Cogent Biosciences Excellent NEWS
Cogent Biosciences (COGT) develops precision therapies for patients with genetically defined diseases. The Company’s primary focusses target different forms of mastocytosis and gastrointestinal stomal tumors (GIST).
The firm’s positive data from Phase 3 PEAK Trial has been studied with the combination of its drug bezuclastinib with Sunitinib.
Many analysts . . .
This content is for paid subscribers.
Trick or Trade
November 24, 2025
